Colchicine is a prescription medication; you should carry the original prescription label and a copy of the prescription. UK travelers to the EU may need to declare the medication at customs and should keep it in its original packaging to avoid confusion with controlled substances.
In the UK, 0.5 mg colchicine tablets often bear the imprint “COL 0.5” or a manufacturer-specific code such as “S 0.5”. The exact appearance can vary between brands, so checking the packaging or pharmacy label is advisable.
Colchicine is not included in routine anti-doping panels for most sports. However, certain competitive organisations may test for it if there is a specific reason, as it is not classified as a performance-enhancing drug.
When stored correctly at room temperature, tablets retain full potency until the expiry date printed on the label. Once the bottle is opened, exposure to humidity can accelerate degradation, so it is best to keep the container tightly sealed.
Concurrent use of colchicine and statins (especially simvastatin or atorvastatin) increases the risk of muscle toxicity. If both are needed, the prescriber may choose a lower-dose statin or monitor creatine kinase levels regularly.
Food does not significantly alter colchicine absorption, but taking the medication with meals can lessen gastrointestinal side effects such as diarrhoea and nausea.
Clinical trials have shown that colchicine reduces recurrence rates of acute pericarditis when added to standard anti-inflammatory therapy. The evidence, though not yet part of the official UK licence, supports its off-label use in selected patients.
Take the missed dose as soon as you remember, provided the next scheduled dose is more than 12 hours away. Do not take two doses at once; if it is near the time of the next dose, skip the missed tablet.
Older adults often have reduced renal function, which raises the risk of colchicine accumulation and toxicity. Dose reduction and closer monitoring of blood counts and kidney function are recommended.
Colchicine does not require refrigeration; storing it at room temperature is sufficient. Keeping it in a cool, dry place protects the tablets from moisture, which could affect their integrity.
Colchicine is a medication classified under pain relief agents, primarily used to treat acute gout flares and certain inherited inflammatory conditions. The active ingredient is colchicine, which is supplied in 0.5 mg pills. In the United Kingdom, colchicine is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is marketed by several manufacturers, but the therapeutic properties stem from the single active compound, colchicine.
Colchicine belongs to the class of microtubule-binding agents. By attaching to tubulin, the building block of microtubules, it prevents the polymerisation of microtubules within cells. This disruption impairs the mobility and activity of neutrophils, the white-blood-cell type most responsible for the intense inflammation seen in gout attacks. The result is a rapid reduction in inflammatory cell migration to the joint, decreasing pain and swelling.
Key pharmacokinetic points:
Colchicine is approved by the MHRA for the treatment of acute gout attacks in adults. It is effective when started within the first 12 hours of symptom onset and can be used as an alternative or adjunct to non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Colchicine holds a licensed indication for prevention of attacks in Familial Mediterranean Fever, an inherited autoinflammatory disorder characterised by recurrent fevers and serositis. Regular daily dosing reduces attack frequency and helps prevent secondary amyloidosis.
Note: In the UK, colchicine is not approved for routine use in other types of arthritis or for chronic pain unrelated to these conditions.
Off-label use requires medical supervision and individualized risk assessment.
These effects are usually transient and may be mitigated by taking the medication with food.
Patients should provide a complete medication list, including over-the-counter products and herbal supplements, before initiating colchicine.
Standard dosing for an acute gout flare (using 0.5 mg tablets):
First dose: 1 mg (two tablets) orally, then 0.5 mg (one tablet) one hour later.
If tolerated, a maintenance dose of 0.5 mg once or twice daily may be prescribed for up to 3 days total.
Dosing must be individualized; the above regimen reflects common practice but clinicians may adjust based on renal/hepatic function and patient tolerance.
Prophylactic dosing for FMF: typically 0.5-1 mg daily, taken at the same time each day.
Administration tips:
Swallow tablets whole with a full glass of water.
They can be taken with or without food; taking them with meals may lessen gastrointestinal upset.
Do not crush or chew the pills.
Missed dose: If a dose is forgotten and the next scheduled dose is > 12 hours away, take the missed dose. Do not double-dose.
Overdose: Signs include severe vomiting, diarrhoea, abdominal pain, muscle weakness, and arrhythmias. Seek urgent medical attention; supportive care and possibly haemodialysis are recommended.
Discontinuation: No tapering is required for short courses. For long-term FMF therapy, abrupt cessation may precipitate attacks; discuss any changes with a clinician.
This article provides educational information about colchicine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
